FDA发布草案指导文件拟简化个体化基因疗法审批流程,Eli Lilly被密苏里州总检察长要求停止340B计划索赔数据要求
STAT+: Pharmalittle: We’re reading about 340B battles, new results for a Lilly weight loss drug, and more
FDA发布草案指导文件,拟通过"合理机制路径"简化部分个体化基因疗法的审批流程。密苏里州总检察长Catherine Hanaway要求Eli Lilly停止要求医院提供340B计划索赔数据以获取折扣药物。该争议反映部分州政府对联邦药品定价政策的监管博弈。
Top of the morning to you. Blue skies, cool breezes, and plenty of chirping birds are enveloping the comfy Pharmalot campus, which is cause to fire up the trusty coffee kettle for a needed cup of stimulation, and we invite you to join us. Remember, a prescription is not required. Our choice today is the seasonal pumpkin spice. Predictable, yes, but also delicious. Meanwhile, here are a few items of interest. Hope you have a smashing day and, of course, do stay in touch. …
The U.S. Food and Drug Administration published draft guidance that would streamline approvals of some individualized gene therapies, a win for rare disease advocates who have criticized the agency approach to these treatments, STAT says. The FDA has continued to require companies to submit separate drug approval applications for each patient’s customized gene therapy, even when they use fundamentally the same approach to target different genes. Advocates argue this creates a prohibitively expensive regulatory burden. The new draft guidance formalizes a “plausible mechanism pathway,” and offers more specific rules for licensing and updating gene editing treatments.
Missouri Attorney General Catherine Hanaway warned Eli Lilly to discontinue its practice of requiring hospitals to provide claims data to receive discounted medicines under a federal program, a sign that more states are pushing back against such moves by drugmakers, STAT notes. In an Oct. 26 cease-and-desist letter sent to the company, Hanaway maintained that Lilly has “broken” its promise to sell its medicines under the 340B Drug Pricing Program to eligible hospitals in the state. As a result, she contended the drugmaker has made “false and misleading statements” and violated state law.
来源:STAT 主站 · statnews.com